ASCO Annual Meeting

Imfinzi Combo Boosts Survival in Resectable Gastric and GEJ Cancer

June 2nd 2025, 1:46pm

Article

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.

Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

June 1st 2025, 12:00pm

Article

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups

June 1st 2025, 12:00pm

Article

Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

June 1st 2025, 12:00pm

Article

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

Trodelvy/Keytruda Extends PFS Versus Chemo/Keytruda in PD -L1+ TNBC

May 31st 2025, 12:10pm

Article

Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC.

Enhertu Improves Survival End Points Vs Cyramza/Paclitaxel in HER2+ GC/GEJ

May 31st 2025, 12:05pm

Article

Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.

Vepdegestrant Boosts Outcomes in ESR1-Mutant ER+/HER2– Advanced Breast Cancer

May 31st 2025, 12:00pm

Article

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.

Braftovi and Erbitux Plus Chemo Improves Outcomes for BRAF V600E+ mCRC

May 30th 2025, 12:00pm

Article

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

May 23rd 2025, 3:00pm

Article

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer

May 22nd 2025, 9:00pm

Article

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.